|   In the News

IFM Lands $55.5M to Launch NewCo Quattro and Discovery Incubator

IFM Therapeutics has raised $55.5 million to launch its third drug subsidiary as well as an incubator, both of which are focused on developing new therapies for inflammatory diseases and cancers.

Read more.


  |   LifeSciVC

Thinking Boldly: Alkermes Acquires Rodin Therapeutics

By Bruce Booth, DPhil, Partner

Today Alkermes announced its acquisition of Rodin Therapeutics, a leader in the field of synaptic dysfunction and neuronal epigenetics.

Read more.


  |   LifeSciVC

The Promise Of Precision Neuroscience And Launch Of Arkuda Therapeutics

By Bruce Booth, DPhil, Partner

Neuroscience has had a tough run of news lately. With Amgen deprioritizing neuro this year, Pfizer doing the same last year, and others like BMS, GSK, and AZ cutting back on CNS a few years earlier, it would seem dark times for neuroscience R&D. Add to that the recent unpredictable complexity around Biogen’s aducanumab, where hugely expensive Phase 3 trials are caught in the maelstrom between negative futility and positive analysis, and it might further question why anyone would want to work in the space.

Read more.


  |   In the News

Atlas, Novo-backed biotech reels in ex-Nimbus CEO Don Nicholson as exec chairman, hooks $50M to conquer anemia

Brian MacDonald’s original foray into treating iron dysregulation by injecting hepcidin, a small peptide hormone key for iron homeostasis, didn’t quite get off the ground. This time, the former GSK executive is taking a fresh approach — by regulating hepcidin expression within the body.

Read more.


  |   From the Trenches

Ode to Patients

Due to meetings in London on a Friday and in Dortmund on the following Monday, I spent the weekend in London.  As I walked the streets appreciating its history, I could not help but think of the history of medicine, as well.  Images of leeches and bloodletting in Tudor times came to mind.  Imagine being a patient back then.

This blog was written by Samantha Truex, CEO of Quench Bio, as part of the From The Trenches feature of LifeSciVC.

Read more.